PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score.

Autor: Bayoğlu İV; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Hüseynov J; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Topal A; Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey., Sever N; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Majidova N; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Çelebi A; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Yaşar A; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Arıkan R; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Işık S; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Hacıoğlu MB; Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey., Ercelep Ö; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Sarı M; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Erdoğan B; Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey., Hacıbekiroğlu İ; Department of Medical Oncology, School of Medicine, Sakarya University, 54290 Sakarya, Turkey., Topaloğlu S; Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey., Köstek O; Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey., Çiçin İ; Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Oct 09; Vol. 12 (19). Date of Electronic Publication: 2023 Oct 09.
DOI: 10.3390/jcm12196420
Abstrakt: Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting.
Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan-Meier and Cox regression analysis.
Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS.
Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje